Hydrogen Therapy Helps Lung Infection Patient with Nerve Disease
- Authors
- Guan-Long Li, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Feng-Cheng Liu
- Journal
- In Vivo
- Year
- 2026
- DOI
- 10.21873/invivo.14337
- Study Type
- Human
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- Taiwan
- Health Condition
- Empyema
- Body System
- Respiratory
TL;DR
In a single complex case of Stage II empyema with CIDP, adjuvant oral molecular hydrogen was associated with clinical recovery and immune shifts toward reduced hyperinflammation and restored regulatory balance.
Key Finding
In this single patient case, molecular hydrogen therapy was associated with a shift in immune cell populations toward a more balanced state, with selective reduction of overactive immune cells and preservation of regulatory immune cells.
Summary
This case report describes a 76-year-old man with two serious conditions—a lung infection (empyema) and a nerve disorder (CIDP)—who was treated with surgery followed by oral molecular hydrogen therapy. Doctors monitored his immune system cells over time and found that hydrogen therapy appeared to help reduce excessive inflammation while preserving immune cells needed for protection, allowing him to recover and leave the hospital.
Practical Takeaway
This is a single case report of one patient with two rare, serious conditions—not evidence that hydrogen water helps healthy people or those with common illnesses. While the immunological changes observed are interesting, case reports cannot prove that hydrogen caused the improvement, since the patient also received surgery and other treatments. Much larger and more rigorous studies would be needed before drawing any conclusions about hydrogen's usefulness.
Abstract
Background/aim: The management of Stage II empyema complicated by chronic inflammatory demyelinating polyneuropathy (CIDP) presents a formidable clinical challenge due to the precarious balance required between aggressive infection control and the modulation of immune-mediated neurological frailty. We report a complex case of comorbid empyema and CIDP successfully managed with a multidisciplinary approach and adjuvant molecular hydrogen (H2) therapy. Case report: A 76-year-old male with CIDP presented with acute respiratory failure secondary to Stage II empyema. Following video-assisted thoracoscopic surgery (VATS) decortication, the patient exhibited systemic hyperinflammation and immune exhaustion. Adjuvant oral molecular hydrogen therapy was initiated during the critical phase. Longitudinal immunophenotyping was performed to monitor the therapeutic response. Clinical recovery coincided with profound immunological remodeling. We observed a cell-specific up-regulation of fas cell surface death receptor (Fas) expression in hyper-activated naïve and effector cytotoxic T cells (Tc), suggesting a H2-facilitated apoptotic clearance of pro-inflammatory lineages. Conversely, the helper T-cell (Th) reservoir was preserved. Recovery was further characterized by the consistent restoration of intermediate and post-germinal center memory B-cell populations, coupled with a substantial augmentation of suppressive T and B-cell subsets (Tregs and Bregs). This shift toward immune homeostasis prevented secondary autoimmune flares and facilitated successful discharge. Conclusion: Molecular hydrogen may act as a systemic bioregulator that fosters immune homeostasis by selectively targeting hyper-activated effector cells while promoting regulatory cell recovery. This dual antioxidant and immunomodulatory capacity positions H2 as a promising adjuvant therapy for complex infectious and neuroinflammatory conditions.